Helping our Clients Turn Hope into Reality

Andelyn Biosciences is a biopharmaceutical CDMO Pioneering Solutions That Turn Hope into Reality™. With 20+ years of experience manufacturing viral vectors, Andelyn’s scientific expertise for development and characterization has led to GMP material being produced for over 75+ worldwide clinical trials and 400+ cGMP clinical batches. Advanced quality systems, full regulatory support, and supply chain vertical integration help accelerate the development and manufacturing of innovative therapies to bring more treatments to more patients.
We support clients through all phases of development and commercialization.
Our Patients Define Us
The name “Andelyn” was chosen to pay tribute to two brave young patients that participated in pivotal clinical trials that make today’s gene therapies possible.
Updates from Andelyn
Blog
November 28, 2022
Following pre-clinical and clinical success, adeno-associated viral vectors (AAVs), have become a leading tool for gene delivery in the treatment...
News
July 11, 2022
John Ketz and Denis Kole speak with Brandy Sargent on The Cell Culture Dish podcast about viral vector production, including current manufacturing challenges, navigating the road to commercialization, and successful scale up strategies.
Blog
February 28, 2022
Observed every year on the last day in February, Rare Disease Day works to raise awareness for rare diseases and...
News
February 14, 2022
Mayo Pujols, CEO of Andelyn Biosciences, discusses how Cell & Gene companies are focusing on reliability and predictability to further advance this innovative therapy.
Our Employees Fuel Our Success
Andelyn is made up of an Inspired, Innovative and Compassionate team that contribute towards a rich company culture. We are always looking for great people who want to do great things.